Reshma Kewalramani, Vertex CEO
FDA lifts hold on Vertex's diabetes stem cell therapy after just two months under the microscope
Vertex Pharmaceuticals has received the FDA go-ahead to continue studies for its diabetes stem cell therapy.
The treatment, which Vertex has attempted to describe as …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
